Vascular Biogenics Ltd

NASDAQ:VBLT  
1.96
+0.19 (+10.73%)
Earnings Announcements

VBL Therapeutics Reports Full Year 2021 Financial Results

Published: 03/23/2022 11:17 GMT
Vascular Biogenics Ltd (VBLT) - Vbl Therapeutics Reports Full Year 2021 Financial Results and Provides Corporate Update.
Vbl Therapeutics - Expects Cash, Cash Equivalents Sufficient to Fund Planned Operating Expenses and Capital Expenditures for at Least Twelve Months.
Revenue is expected to be $1.16 Million
Adjusted EPS is expected to be -$0.11

Next Quarter Revenue Guidance is expected to be $0.12 Million
Next Quarter EPS Guidance is expected to be -$0.13

More details on our Analysts Page.